Serum soluble toll-like receptor 2 and 4 as diagnostic and prognostic biomarkers for non-Hodgkin lymphoma.
ELISA
NHL
TLR
sTLR2
sTLR4
Journal
Contemporary oncology (Poznan, Poland)
ISSN: 1428-2526
Titre abrégé: Contemp Oncol (Pozn)
Pays: Poland
ID NLM: 101233223
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
06
2020
accepted:
22
08
2020
entrez:
25
11
2020
pubmed:
26
11
2020
medline:
26
11
2020
Statut:
ppublish
Résumé
To assess the serum levels of soluble toll-like receptor 2 (sTLR2) and soluble toll-like receptor 4 (sTLR4) in a group of patients with non-Hodgkin lymphoma (NHL) and to investigate their correlations with the clinicopathological parameters of NHL. Fifty patients with early-stage NHL and 50 patients with advanced-stage NHL along with 50 age- and sex-matched healthy volunteers were enrolled in the study. Serum levels of sTLR2 and sTLR4 were measured using enzyme-linked immunosorbent assay (ELISA). A significant increase in the serum levels of sTLR2 (pg/ml) was detected in early stage NHL (group I) (2381.1 ±1822.0) and advanced stage NHL (group II) (2864.9 ±2599.9) when compared to levels in the control group (1229.2 ±70.55) ( sTLR2 and sTLR4 might be diagnostic and prognostic biomarkers for NHL.
Identifiants
pubmed: 33235541
doi: 10.5114/wo.2020.100270
pii: 42187
pmc: PMC7670186
doi:
Types de publication
Journal Article
Langues
eng
Pagination
157-162Informations de copyright
Copyright © 2020 Termedia.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Hepatol Res. 2014 Jul;44(7):769-78
pubmed: 23742263
Nutrients. 2018 Feb 13;10(2):
pubmed: 29438282
Lab Hematol. 2005;11(1):47-61
pubmed: 15790553
Int Immunol. 2005 Jan;17(1):1-14
pubmed: 15585605
Acta Orthop. 2017 Jun;88(3):326-333
pubmed: 28093922
Int J Rheum Dis. 2016 Jul;19(7):685-92
pubmed: 25123610
Oncotarget. 2016 Jun 28;7(26):40106-40114
pubmed: 27223258
Ann Hematol. 2014 Nov;93(11):1859-65
pubmed: 24912772
Nat Rev Cancer. 2009 Jan;9(1):57-63
pubmed: 19052556
Cell Mol Biol Lett. 2009;14(2):248-72
pubmed: 19096763
J Immunol. 2003 Dec 15;171(12):6680-9
pubmed: 14662871
BMC Immunol. 2014 Nov 19;15:55
pubmed: 25406630
J Immunol. 2000 Dec 15;165(12):6682-6
pubmed: 11120784
Exp Mol Pathol. 2010 Dec;89(3):284-90
pubmed: 20800061
Nat Rev Immunol. 2005 Jun;5(6):446-58
pubmed: 15928677
Front Immunol. 2016 Aug 02;7:291
pubmed: 27531999
Curr Biol. 2011 Jul 12;21(13):R488-93
pubmed: 21741580